Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. It also focuses on generic oncology injectable products. The company offers generic oncology products, such as temozolomide, capecitabine, and erlotinib. It also provides injectable generic chemotherapy drugs, such as pemetrexed for the treatment of non-small cell lung cancer and other indications; and bortezomib to treat multiple myeloma and other indications. In addition, the company develops PARP-1 inhibitors for cancer treatment. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.